DUTCH Test Results: Evidence-Based Ways to Improve Your Numbers

What the DUTCH Test Actually Measures

The DUTCH test is not a single hormone number. It is a panel of hormone metabolites captured in dried urine collected at four or five time points across a waking day, typically including two daytime, one evening, and one overnight or early-morning collection.

The panel covers three main domains.

Adrenal Output

Free cortisol at each collection point draws a curve showing whether your peak is appropriately high in the morning and falls through the day. The DUTCH also reports total cortisol metabolites (THF + aTHF + THE), which reflect overall cortisol production rather than just what is left unbound. DHEA-S appears as a surrogate for adrenal androgen reserve. Research published in Endocrine Reviews confirms that the diurnal cortisol pattern, not a single cortisol value, is the meaningful clinical signal in adrenal assessment.

Estrogen Metabolites and Detoxification Pathways

The DUTCH separates estrogens into estrone (E1), estradiol (E2), and estriol (E3), and critically, it reports the downstream metabolites: 2-hydroxyestrone (2-OHE1), 4-hydroxyestrone (4-OHE1), and 16-alpha-hydroxyestrone (16-OHE1). The ratio of 2-OHE1 to 16-OHE1 has been studied in relation to breast cancer risk. A 2012 meta-analysis in Cancer Epidemiology, Biomarkers and Prevention found higher 2:16 ratios were associated with lower breast cancer risk in postmenopausal women, though the evidence is observational and the DUTCH alone cannot diagnose cancer risk.

The panel also shows 2-methoxyestrone (2-MeOE1), a marker of methylation capacity. Low 2-MeOE1 relative to 2-OHE1 points to sluggish COMT enzyme activity, which is relevant to mood, pain sensitivity, and estrogen clearance.

Progesterone and Androgen Metabolites

Progesterone does not appear directly because urine captures its breakdown products: pregnanediol and pregnanetriol. Testosterone metabolites include 5-alpha-androstanediol glucuronide, etiocholanolone, and androsterone, giving a picture of androgen activity and 5-alpha-reductase activity. This matters in PCOS, female pattern hair loss, and hormonal acne.

Normal DUTCH Test Ranges by Life Stage

There is no single universal "normal." Reference ranges on a DUTCH report are population-derived from the Precision Analytical laboratory database and are presented as shaded zones on the report. The ranges shift substantially by life stage, which is why the report you receive has a field for the collection day of your menstrual cycle (if you are cycling) or your menopausal status.

Reproductive Years (Cycling Women)

For a woman with regular cycles, the standard collection window is days 19 to 22 of a 28-day cycle, when progesterone metabolites should be at their post-ovulation peak. Collecting outside this window makes progesterone metabolites uninterpretable. The American College of Obstetricians and Gynecologists recognizes mid-luteal progesterone as the standard marker of ovulation confirmation, and the DUTCH metabolite equivalent tracks the same biology.

Estradiol in cycling women varies enormously by cycle phase. Follicular phase levels run roughly 30 to 300 pg/mL equivalent in urine metabolites; mid-cycle surge reaches two to three times that. If your DUTCH was collected at a random point in your cycle, estrogen numbers mean very little without phase context.

Perimenopause

This is where DUTCH results become hardest to interpret and most clinically interesting. Perimenopause brings erratic estradiol swings, declining progesterone, and often a compensatory rise in FSH. The Menopause Society (formerly NAMS) notes that hormone levels in perimenopause fluctuate day to day, so a single collection can capture a high-estrogen surge or a low-estrogen trough. Repeat testing, or testing with symptoms in mind, gives more actionable information than a one-time panel.

Post-Menopause (No Hormone Therapy)

In a post-menopausal woman not using hormone therapy, estrogen metabolites are expected to be low across the board. Elevated estrone metabolites in this context can reflect peripheral aromatization of androgens in adipose tissue, which is relevant if you are concerned about estrogen-sensitive conditions.

Post-Menopause (Using Hormone Therapy)

If you use transdermal or vaginal estradiol, your DUTCH estrogen metabolites will reflect both endogenous production and the therapeutic dose. The ratio markers (2:16, methylation) remain interpretable, but absolute estrogen metabolite levels must be read against your prescribed dose. Oral estrogen is processed through first-pass hepatic metabolism in a way that alters the metabolite profile versus transdermal; a study in Menopause found significantly different urinary estrogen metabolite patterns between oral and transdermal users, which means route of administration must be documented on any DUTCH request.

What a High Result Means and How to Lower Specific Markers

"High" depends entirely on which marker is elevated. Treating all high values the same way is a common mistake.

High Total Cortisol Metabolites (High Overall Cortisol Production)

Elevated THF + aTHF + THE points to chronically high cortisol output. Common drivers include sleep deprivation, caloric restriction, high-intensity exercise without adequate recovery, and psychological stress. Research from the Journal of Clinical Endocrinology and Metabolism demonstrated that sleep restriction of six hours per night for one week raised 24-hour urinary cortisol excretion in healthy adults.

Evidence-based strategies to lower total cortisol metabolites:

• Sleep: Target 7 to 9 hours. Even partial sleep extension meaningfully reduces HPA axis output. A randomized trial in SLEEP showed that extending sleep in habitually short sleepers reduced salivary cortisol awakening response within two weeks.
• Exercise calibration: Moderate aerobic exercise (150 minutes per week) lowers basal cortisol; daily high-intensity training without rest days raises it. The American College of Sports Medicine guidelines for women include at least two rest or low-intensity days per week.
• Ashwagandha: A 60-day randomized controlled trial in adults with chronic stress found that ashwagandha root extract (300 mg twice daily) reduced serum cortisol by 27.9% versus placebo. This is among the more replicated adaptogen findings, though the DUTCH-specific effects have not been trialed.
• Phosphatidylserine: A 2004 study in Stress found 400 mg/day blunted exercise-induced cortisol rise in men. Female-specific data are thin; extrapolation is noted.

High 16-Alpha-Hydroxyestrone (Favoring the 16-OH Pathway)

A low 2:16-OHE1 ratio (below roughly 2.0) suggests your estrogen detoxification is favoring the 16-alpha pathway over the 2-hydroxy pathway. This is about metabolism, not production, so interventions target Phase I and Phase II liver detoxification.

• Cruciferous vegetables and I3C/DIM: Indole-3-carbinol (I3C), found in broccoli, cauliflower, and cabbage, shifts estrogen hydroxylation toward the 2-OH pathway. A randomized crossover trial in Cancer Epidemiology, Biomarkers and Prevention showed that 500 mg/day I3C for four weeks increased the urinary 2:16-OHE1 ratio from 1.06 to 2.08. Diindolylmethane (DIM), the active metabolite, is available as a supplement at doses of 100 to 300 mg/day and avoids the need for gastric acid conversion that I3C requires.
• Dietary fiber: Adequate fiber (25 g/day for women per Dietary Guidelines for Americans) supports estrogen excretion through the gut. Low fiber allows beta-glucuronidase activity in the gut to deconjugate excreted estrogens, allowing reabsorption.
• Alcohol reduction: Alcohol impairs hepatic estrogen metabolism. Even moderate intake (one drink daily) raises circulating estrogens. A Women's Health Study analysis found each 10 g/day alcohol increment raised plasma estradiol by 2.6 pg/mL in postmenopausal women on hormone therapy.
• Body weight: Adipose tissue aromatizes androgens to estrone. A 5 to 10% reduction in body weight in overweight women reduces circulating estrogens measurably per data from the Women's Health Initiative.

High 4-Hydroxyestrone

The 4-OH metabolite is the most genotoxic estrogen pathway. It requires adequate methylation (via COMT enzyme and SAMe) for safe clearance. A low 2-MeOE1:2-OHE1 ratio alongside elevated 4-OHE1 points to a methylation bottleneck.

Strategies here are specifically methylation-support:

• Methylated B vitamins: Methylfolate (5-MTHF), methylcobalamin (B12), and riboflavin (B2) support COMT activity. Women with the MTHFR C677T variant have reduced folate conversion and may need supplemental 5-MTHF at 400 to 800 mcg/day, which is also the CDC-recommended folic acid dose for reproductive-age women.
• Magnesium: COMT is a magnesium-dependent enzyme. Dietary insufficiency is common; the RDA for adult women is 310 to 320 mg/day, and many women fall short.

High Androgens or Elevated 5-Alpha-Reductase Activity (High Androsterone Relative to Etiocholanolone)

This pattern is common in PCOS. Elevated 5-alpha-reductase activity drives androsterone preferentially and correlates with androgenic symptoms like acne, hirsutism, and female pattern hair loss.

• Spearmint tea: A pilot RCT in Phytotherapy Research found twice-daily spearmint tea reduced free testosterone in women with PCOS after 30 days, with a trend toward reduced hirsutism.
• Inositol: Myo-inositol (2 g twice daily) is studied in PCOS for insulin sensitization, which indirectly lowers LH-driven androgen production. ASRM and ESHRE include inositol in their PCOS guidance as a low-risk adjunct.
• Low glycemic diet: Insulin amplifies ovarian androgen production. A systematic review in Nutrients found low-GI diets reduced free androgen index by up to 33% in women with PCOS over 12 weeks.

What a Low Result Means and How to Raise Specific Markers

Low Total Cortisol Metabolites (Low Overall Cortisol Output)

This is sometimes called "adrenal fatigue" in popular media, a term the Endocrine Society explicitly does not recognize as a medical diagnosis. What the DUTCH does show is whether cortisol production and clearance are low. True adrenal insufficiency (Addison's disease) requires serum ACTH stimulation testing, not urine metabolites alone.

For low-normal cortisol patterns without frank adrenal disease, evidence-supported approaches include:

• Sleep prioritization and circadian anchoring: Going to bed and waking at consistent times supports the HPA axis's natural cortisol rhythm. Research from the National Institute of General Medical Sciences confirms that irregular sleep timing blunts the cortisol awakening response.
• Strategic reduction of overtraining: Women in energy deficit with low cortisol metabolites often have relative energy deficiency in sport (RED-S). The IOC consensus statement on RED-S identifies blunted cortisol as one of the endocrine consequences.
• Protein adequacy: Cortisol synthesis requires adequate substrate. A protein intake below 1.0 g/kg/day in active women is associated with HPA axis suppression in endurance athletes.

Low Progesterone Metabolites (Low Pregnanediol-3-Glucuronide)

Low luteal progesterone metabolites in a cycling woman typically reflect anovulation or a short, inadequate luteal phase. This is relevant to fertility and to perimenopausal symptoms.

• In reproductive years, the first clinical step is confirming ovulation with tracking (basal body temperature, LH surge, mid-luteal serum progesterone). If anovulatory cycles are confirmed, evaluation for PCOS, thyroid disease, or hypothalamic amenorrhea is indicated per ACOG Practice Bulletin on Anovulatory Bleeding.
• Vitex agnus-castus (chaste tree) at 20 to 40 mg/day has a small body of evidence for supporting luteal phase length. A Cochrane review found limited but suggestive data for cycle regularity; it is not a substitute for clinical evaluation.
• In perimenopause, low progesterone metabolites are expected and often warrant discussion of progesterone therapy, particularly micronized progesterone (Prometrium, Utrogestan), which has a more favorable safety profile than synthetic progestins per The Menopause Society position statement.

Low DHEA-S

DHEA-S declines naturally with age (adrenopause). By age 70, levels average 10 to 20% of peak young-adult values. Low DHEA-S is also seen in women with HPA axis suppression from chronic stress, autoimmune disease, or prolonged corticosteroid use.

Over-the-counter DHEA supplementation at 25 to 50 mg/day is legal in the United States but not FDA-approved for adrenal restoration. For postmenopausal women specifically, intravaginal DHEA (prasterone, Intrarosa 6.5 mg/dose) is FDA-approved for dyspareunia due to vulvovaginal atrophy. For systemic DHEA supplementation, consult a clinician before starting; excess DHEA converts to androgens and estrogens and can worsen acne, hair loss, or estrogen-sensitive conditions.

DUTCH Test in PCOS, Perimenopause, and Thyroid-Related Hormone Changes

This framework for reading DUTCH results by condition is not published as a standalone clinical guide elsewhere. Use it alongside your clinician's interpretation, not as a substitute for it.

PCOS: Expect elevated total androgens and androgen metabolites, often with elevated 5-alpha-reductase activity. Cortisol metabolites may be high due to associated insulin resistance driving adrenal androgen production. The 2:16 estrogen ratio may be skewed if obesity-related aromatization is present. First-line interventions target insulin: metformin at 500 to 2000 mg/day per ASRM guidelines and lifestyle modification (5 to 10% weight loss where indicated).

Perimenopause: The most common DUTCH pattern in perimenopause is erratic estradiol metabolites, falling progesterone metabolites, and either a flat or still-normal cortisol curve. Androgen metabolites often fall alongside estrogen but 5-alpha-reductase activity can remain elevated, driving scalp hair thinning. Perimenopause is not a disease; some women with a poor progesterone-to-estrogen metabolite ratio and symptoms benefit from low-dose micronized progesterone, a conversation to have with a menopause-trained clinician.

Thyroid disease: Hypothyroidism slows Phase I hepatic liver enzymes, which reduces the conversion of estradiol to its downstream metabolites. Women with untreated hypothyroidism may show lower overall estrogen metabolites despite adequate estrogen production. Postpartum thyroiditis, affecting an estimated 5 to 10% of postpartum women, can produce swings in both thyroid hormones and HPA axis output visible on a DUTCH if collected during an active thyroid phase.

Pregnancy, Lactation, and the DUTCH Test

The DUTCH test is not validated for use in pregnancy. Pregnancy produces dramatic, rapid changes in all hormones measured by the panel. Progesterone rises to levels 10 to 100 times non-pregnant values; cortisol rises by the third trimester due to placental CRH production; and estrogen metabolite patterns are dominated by placental estriol. Any result collected during pregnancy would be uninterpretable against standard reference ranges.

Lactation: Prolactin suppresses the HPG axis during exclusive breastfeeding, causing low estrogen and anovulation. A DUTCH collected during lactational amenorrhea would show low estrogen metabolites and absent progesterone metabolites, reflecting normal lactational physiology, not a pathological hormone deficit requiring supplementation.

Contraception: Hormonal contraceptives alter every domain of the DUTCH. Combined oral contraceptives (COCs) suppress endogenous estrogen and progesterone production, making the progesterone metabolite section uninterpretable. COCs also affect cortisol-binding globulin, raising total cortisol but not free cortisol. The DUTCH Plus does report free cortisol separately, partially mitigating this, but most DUTCH results collected on COCs should be interpreted only for the adrenal cortisol curve and are not useful for sex hormone metabolite assessment. If you are trying to assess your baseline hormone metabolism, discuss stopping or pausing hormonal contraception with your clinician before testing. Never stop contraception without a plan; if your contraceptive method is also managing a condition like endometriosis or PCOS, that conversation needs clinical supervision.

Women planning pregnancy should be aware that the lifestyle changes that improve estrogen metabolism (cruciferous vegetables, DIM/I3C, methylated B vitamins including folic acid) largely align with preconception nutrition guidelines from ACOG, with the exception that DIM supplementation at high doses has not been studied in early pregnancy and should be stopped once a pregnancy is confirmed until safety data exist.

Who This Testing Is Right For and Who Should Be Cautious

The DUTCH test is most appropriate for women who have:

• Cyclical symptoms that suggest a luteal phase or estrogen dominance pattern (bloating, mood changes, breast tenderness in the two weeks before a period)
• Perimenopausal symptoms they want characterized before deciding on hormone therapy
• PCOS with androgen-mediated symptoms not fully explained by standard labs
• Unexplained fatigue with a question about HPA axis function that a single serum cortisol does not answer
• Already started hormone therapy and want to assess metabolite ratios rather than just serum levels

The DUTCH test is less useful or potentially misleading for women who:

• Are pregnant or breastfeeding (see above)
• Are on oral contraceptives and want sex hormone metabolite interpretation
• Want a diagnosis of adrenal insufficiency (requires serum ACTH stimulation, not urine metabolites)
• Have known adrenal tumors or pituitary disease (requires specialist imaging and serum testing)

The Endocrine Society does not currently endorse dried urine testing as a replacement for standard endocrine workups in formally diagnosed adrenal or ovarian pathology. The DUTCH is a functional, context-providing tool best used alongside, not instead of, standard-of-care labs.

Evidence Gaps to Know About

Women have been consistently underrepresented in hormone metabolism research. Most of the foundational pharmacokinetic work on cortisol clearance and estrogen hydroxylation was conducted in mixed-sex or predominantly male cohorts and extrapolated to women. The DUTCH-specific intervention trials (studies that randomize women to an intervention, measure DUTCH results before and after, and report clinical outcomes) essentially do not exist in the published literature as of 2025. What exists is:

• Physiologically plausible mechanistic evidence linking the interventions above to the relevant enzyme pathways
• Clinical outcome trials on individual interventions (I3C, DIM, ashwagandha, inositol) that used serum or spot-urine hormone measures, not full DUTCH panels
• Observational data on estrogen metabolite ratios and disease risk (the 2:16 literature)

This means your clinician is applying evidence from adjacent literatures, not from DUTCH-outcome RCTs. That is not a reason to dismiss the test; it is a reason to hold any specific numerical target loosely and to prioritize symptom-guided goals alongside metabolite goals. The Menopause Society consistently emphasizes that the woman's symptom burden, quality of life, and clinical picture drive treatment decisions, not a laboratory value alone.